Back to top

Analyst Blog

Bayer (BAYRY - Analyst Report) recently initiated a phase III study on BAY 94-9027 in children (up to 12 years of age) for the treatment of hemophilia A.

The phase III PROTECT VIII study (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII) will evaluate whether the candidate can be used prophylactically to prolong the duration of protection from bleeding for up to one week, while also being used to treat acute bleeds.

The study will be a multicenter, multinational, partially randomized, open-label trial. Bayer intends to enroll around 50 previously treated children from across the world for the phase III study. These children suffering from severe hemophilia A have a history of at least 50 exposure days (ED) with any FVIII product. These children will also be given an option to participate in an optional extension study.

Bayer is also conducting the PROTECT VIII study in adults suffering from hemophilia A. The company has already completed enrolment in this trial.

We remind investors that in May 2013, Bayer had discontinued the phase II/III TRUST (TReatment with Unique recombinant rFVIIa STudy) study on BAY 86-6150. The study was evaluating the efficacy and safety of the candidate in patients suffering from hemophilia A or hemophilia B with inhibitors.

A neutralizing antibody was detected during the course of the study. Since patient safety was the primary objective of the study, Bayer discontinued the BAY 86-6150 trial as a precautionary measure.

Bayer already has Kogenate in its product portfolio for the treatment of haemophilia. We note that companies like Biogen Idec Inc. (BIIB - Analyst Report) are also developing therapies targeting the hemophilia market.

Bayer, a large-cap pharma company, presently carries a Zacks Rank #4 (Sell). Meanwhile, other large-cap stocks such as Novo Nordisk (NVO - Analyst Report) currently look more attractive with a Zacks Rank #2 (Buy). Other pharma stocks such as Jazz Pharmaceuticals (JAZZ - Analyst Report) carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%